# A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

> **NCT01226901** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3 (actual)

## Conditions studied

- Neoplasms
- Solid Tumors

## Interventions

- **DRUG:** MK-4827

## Key facts

- **NCT ID:** NCT01226901
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226901, "A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01226901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*